626 results on '"Kaitu'u-Lino, Tu'uhevaha"'
Search Results
202. Chorioamnionitis Occurring in Women With Preterm Rupture of the Fetal Membranes Is Associated With a Dynamic Increase in mRNAs Coding Cytokines in the Maternal Circulation.
- Author
-
Stock, Owen, Gordon, Lavinia, Kapoor, Jada, Walker, Susan P., Whitehead, Clare, Kaitu'u-Lino, Tu'uhevaha J., Pell, Gabrielle, Hannan, Natalie J., and Tong, Stephen
- Subjects
MESSENGER RNA ,FETAL membranes ,PREGNANCY complications ,INFLAMMATION ,MATERNAL health - Abstract
Background: Preterm prelabor rupture of the fetal membranes (PPROM) is a significant contributor to the morbidity and mortality of preterm birth, particularly in the setting of chorioamnionitis. No sensitive or specific diagnostic or predictive test currently exists for the accurate diagnosis of chorioamnionitis. Our aim was to measure messenger RNA (mRNA) coding cytokines in the maternal blood and examine whether they were increased in association with chorioamnionitis at delivery. Methods/Results: We performed a prospective cohort study of women recruited with PPROM at a mean gestational age of 28.9 weeks at risk of developing chorioamnionitis. Blood was sampled from participants, and the expression of mRNA coding for proinflammatory genes was measured in women with and without chorioamnionitis at the time of delivery as well as gestation-matched healthy controls. Expression was measured using quantitative polymerase chain reaction (PCR) and also digital PCR. Interleukin 1β (IL1B) mRNA expression in maternal blood was elevated in women with chorioamnionitis compared to gestation-matched controls. Importantly, among women admitted with PPROM, digital PCR confirmed a significant increase in IL1B expression in maternal blood in women with chorioamnionitis compared to women without chorioamnionitis. Polymerase chain reaction array revealed that CD14, nuclear factor of κ light polypeptide gene enhancer in B-cells 1 (NFKB1), and tumor necrosis factor receptor super family-interacting serine-threonine kinase 1 mRNA were significantly increased in women with chorioamnionitis compared to controls. Digital PCR confirmed that NFKB1 mRNA was significantly increased in patients with chorioamnionitis compared to controls and that CD14 levels increased over time in patients with PPROM having chorioamnionitis. Conclusion: Measuring circulating proinflammatory mRNA in women with PPROM may distinguish those with chorioamnionitis from those without, in turn providing better targeted therapies and appropriate timing of delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
203. Sofalcone Upregulates the Nuclear Factor (Erythroid-Derived 2)-Like 2/Heme Oxygenase-1 Pathway, Reduces Soluble fms-Like Tyrosine Kinase-1, and Quenches Endothelial Dysfunction.
- Author
-
Kenji Onda, Tong, Stephen, Anzu Nakahara, Mei Kondo, Hideaki Monchusho, Toshihiko Hirano, Kaitu'u-Lino, Tu'uhevaha, Beard, Sally, Binder, Natalie, Tuohey, Laura, Brownfoot, Fiona, and Hannan, Natalie J.
- Abstract
Preeclampsia is a severe complication of pregnancy, characterized by hypertension, oxidative stress, and severe endothelial dysfunction. Antiangiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin, play key pathophysiological roles in preeclampsia. Heme oxygenase-1 (HO-1) is a cytoprotective, antioxidant enzyme reported to be downregulated in preeclampsia. Studies propose that inducing HO-1 may also decrease sFlt-1 production. Sofalcone, a gastric antiulcer agent in clinical use, is known to induce HO-1 in gastric epithelium. We aimed to investigate whether sofalcone induces HO-1 and reduces sFlt-1 release from primary human placental and endothelial cells and blocks endothelial dysfunction in vitro. We isolated human trophoblasts and endothelial cells (human umbilical vein endothelial cells) and also used uterine microvascular cells. We investigated the effects of sofalcone on (1) HO-1 production, (2) activation of the nuclear factor (erythroid-derived 2)-like 2 pathway, (3) sFlt-1 and soluble endoglin release, (4) tumor necrosis factor α-induced monocyte adhesion and vascular cell adhesion molecule upregulation, and (5) endothelial tubule formation. Sofalcone potently increased HO-1 mRNA and protein in both primary trophoblasts and human umbilical vein endothelial cells. Furthermore, sofalcone treatment caused nuclear translocation of nuclear factor (erythroid-derived 2)-like 2 and transactivation of other nuclear factor (erythroid-derived 2)-like 2 responsive genes (NQO1, TXN, and GCLC). Importantly, sofalcone significantly decreased the secretion of sFlt-1 from primary human trophoblasts. Sofalcone potently suppressed endothelial dysfunction in 2 in vitro models, blocking tumor necrosis factor α-induced monocyte adhesion and vascular cell adhesion molecule 1 expression in human umbilical vein endothelial cells. These results indicate that in primary human tissues, sofalcone can potently activate antioxidant nuclear factor (erythroid-derived 2)-like 2/HO-1 pathway, decrease sFlt-1 production, and ameliorate endothelial dysfunction. We propose that sofalcone is a novel therapeutic candidate for preeclampsia. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
204. Neutrophil depletion retards endometrial repair in a mouse model
- Author
-
Kaitu’u-Lino, Tu’uhevaha J., primary, Morison, Naomi B., additional, and Salamonsen, Lois A., additional
- Published
- 2006
- Full Text
- View/download PDF
205. Complex expression patterns support potential roles for maternally derived activins in the establishment of pregnancy in mouse
- Author
-
Jones, Rebecca L, primary, Kaitu’u-Lino, Tu’uhevaha J, additional, Nie, Guiying, additional, Sanchez-Partida, L Gabriel, additional, Findlay, Jock K, additional, and Salamonsen, Lois A, additional
- Published
- 2006
- Full Text
- View/download PDF
206. Use of Metformin to Prolong Gestation in Preterm Pre-eclampsia: Randomised, Double Blind, Placebo Controlled Trial
- Author
-
Cluver, Catherine A., Hiscock, Richard, Decloedt, Eric H., Hall, David R., Schell, Sonja, Mol, Ben W., Brownfoot, Fiona, Kaitu'u-Lino, Tu'uhevaha J., Walker, Susan P., and Tong, Stephen
- Abstract
(Abstracted from BMJ2021;374:n2103)Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality, particularly when presenting preterm. Because the only treatment for preeclampsia is delivery, preterm preeclampsia often leads to preterm delivery placing the neonate at risk of major neonatal disability and death.
- Published
- 2022
- Full Text
- View/download PDF
207. Quantitative Point of Care Tests for Timely Diagnosis of Early‐Onset Preeclampsia with High Sensitivity and Specificity.
- Author
-
Masoumeh Ghorbanpour, Sahar, Wen, Shihui, Kaitu'u‐Lino, Tu'uhevaha J, Hannan, Natalie J., Jin, Dayong, and McClements, Lana
- Subjects
- *
PREECLAMPSIA , *POINT-of-care testing , *SENSITIVITY & specificity (Statistics) , *CARDIOVASCULAR diseases , *DIAGNOSIS , *CD44 antigen - Abstract
Preeclampsia is a heterogeneous and multiorgan cardiovascular disorder of pregnancy. Here, we report the development of a novel strip‐based lateral flow assay (LFA) using lanthanide‐doped upconversion nanoparticles conjugated to antibodies targeting two different biomarkers for detection of preeclampsia. We first measured circulating plasma FKBPL and CD44 protein concentrations from individuals with early‐onset preeclampsia (EOPE), using ELISA. We confirmed that the CD44/FKBPL ratio is reduced in EOPE with a good diagnostic potential. Using our rapid LFA prototypes, we achieved an improved lower limit of detection: 10 pg ml−1 for FKBPL and 15 pg ml−1 for CD44, which is more than one order lower than the standard ELISA method. Using clinical samples, a cut‐off value of 1.24 for CD44/FKBPL ratio provided positive predictive value of 100 % and the negative predictive value of 91 %. Our LFA shows promise as a rapid and highly sensitive point‐of‐care test for preeclampsia. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
208. Variable effect of maternal oral glucose load on circulating cell-free placental mRNAs.
- Author
-
MacDonald, Teresa Mary, Kaitu'u-Lino, Tu'uhevaha Joy, Walker, Susan Philippa, Dane, Kirsten Margaret, Lockie, Elizabeth Beatrice, Tong, Stephen, Whitehead, Clare Louise, and Hui, Lisa
- Subjects
- *
GLUCOSE , *MESSENGER RNA , *FASTING , *PLACENTA , *GENETIC transcription - Abstract
Background: It is not known whether fasting affects levels of circulating placenta-specific transcripts.Objective: To assess whether a glucose load affects circulating placenta-specific transcripts.Method: RNA was extracted from paired blood samples (fasting and 1-h post 75 g oral glucose) from 22 women. Placenta-specific genes were measured by RT-qPCR.Results: There was no change in ADM, CSH1, PAPPA2, PSG1 or TAC3 expression between fasting and post-glucose states. However, HTRA1 decreased after glucose load.Conclusion: Maternal fasting state does not influence expression of the majority of placenta-specific genes but may need to be accounted for when validating biomarkers of placental disease. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
209. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin.
- Author
-
Kaitu’u-Lino, Tu’uhevaha J., Tong, Stephen, Beard, Sally, Hastie, Roxanne, Tuohey, Laura, Brownfoot, Fiona, Onda, Kenji, and Hannan, Natalie J.
- Abstract
Objectives Soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) are the most studied molecules in preeclampsia. However, most trophoblast cell lines do not secrete both these factors. Thus, we set out to characterize protocols to functionally investigate sFlt-1 and sEng from primary trophoblast. Study design Primary trophoblasts were isolated from term placenta by percoll gradient, then negative selection using a CD9 antibody. Purity was assessed by cytokeratin 7 immunostaining. We first examined the effects of CD9 negative selection on sFlt-1, sEng and hCG secretion and the ability of forskolin to enhance syncytialization. We then examined the effects of hypoxia on sFlt-1 production and assessed gene knockdown using siRNA. Results CD9 negative selection produced a pure population of primary trophoblasts. Secretion of sEng was 5-fold lower when CD9-positive cells were removed, sFlt1 was unchanged, and hCG was significantly increased. hCG analysis of the purified population indicated spontaneous syncytialization, which was not enhanced by forskolin. Forskolin similarly did not alter sFlt-1 secretion. Hypoxia significantly increased sFlt-1 secretion as expected. Importantly, high gene silencing efficiencies were readily achieved. Conclusion In conclusion, we present a protocol that yields primary trophoblasts of high purity that produce abundant sFlt-1 and low but detectable levels of sEng. Furthermore, these cells are readily amenable to gene silencing by siRNAs and hence suitable for functional studies. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
210. Circulating SPINT1 Is Reduced in a Preeclamptic Cohort with Co-Existing Fetal Growth Restriction.
- Author
-
Murphy, Ciara N., Cluver, Catherine A., Walker, Susan P., Keenan, Emerson, Hastie, Roxanne, MacDonald, Teresa M., Hannan, Natalie J., Brownfoot, Fiona C., Cannon, Ping, Tong, Stephen, and Kaitu'u-Lino, Tu'uhevaha J.
- Subjects
FETAL growth retardation ,SMALL for gestational age ,PLACENTAL growth factor ,PREECLAMPSIA ,STILLBIRTH - Abstract
Fetal growth restriction (FGR), when undetected antenatally, is the biggest risk factor for preventable stillbirth. Maternal circulating SPINT1 is reduced in pregnancies, which ultimately deliver small for gestational age (SGA) infants at term (birthweight < 10th centile), compared to appropriate for gestational age (AGA) infants (birthweight ≥ 10th centile). SPINT1 is also reduced in FGR diagnosed before 34 weeks' gestation. We hypothesised that circulating SPINT1 would be decreased in co-existing preterm preeclampsia and FGR. Plasma SPINT1 was measured in samples obtained from two double-blind, randomised therapeutic trials. In the Preeclampsia Intervention with Esomeprazole trial, circulating SPINT1 was decreased in women with preeclampsia who delivered SGA infants (n = 75, median = 18,857 pg/mL, IQR 10,782–29,890 pg/mL, p < 0.0001), relative to those delivering AGA (n = 22, median = 40,168 pg/mL, IQR 22,342–75,172 pg/mL). This was confirmed in the Preeclampsia Intervention 2 with metformin trial where levels of SPINT1 in maternal circulation were reduced in SGA pregnancies (n = 95, median = 57,764 pg/mL, IQR 42,212–91,356 pg/mL, p < 0.0001) compared to AGA controls (n = 40, median = 107,062 pg/mL, IQR 70,183–176,532 pg/mL). Placental Growth Factor (PlGF) and sFlt-1 were also measured. PlGF was significantly reduced in the SGA pregnancies, while ratios of sFlt-1/SPINT1 and sFlt1/PlGF were significantly increased. This is the first study to demonstrate significantly reduced SPINT1 in co-existing FGR and preeclamptic pregnancies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
211. Corin, an enzyme with a putative role in spiral artery remodeling, is up-regulated in late secretory endometrium and first trimester decidua.
- Author
-
Kaitu'u-Lino, Tu'uhevaha J, Ye, Louie, Tuohey, Laura, Dimitriadis, Evdokia, Bulmer, Judith, Rogers, Peter, Menkhorst, Ellen, Van Sinderen, Michelle, Girling, Jane E, Hannan, Natalie, and Tong, Stephen
- Published
- 2013
- Full Text
- View/download PDF
212. MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin.
- Author
-
Kaitu'u-Lino, Tu'uhevaha J., Palmer, Kirsten, Tuohey, Laura, Louie Ye, and Stephen Tong
- Subjects
- *
PREECLAMPSIA , *PLACENTA , *OBSTETRICS , *PROTEOLYTIC enzymes , *TARGETED drug delivery - Abstract
Preeclampsia is a major pregnancy complication, characterized by severe endothelial dysfunction, hypertension and maternal end-organ damage. Soluble endoglin is an anti-angiogenic protein released from placenta and thought to play a central role in causing the endothelial dysfunction and maternal organ injury seen in severe preeclampsia. We recently reported MMP-14 was the protease producing placentally-derived soluble endoglin by cleaving full-length endoglin present on the syncytiotrophoblast surface. This find identifies a specific drug target for severe preeclampsia; interfering with MMP- 14 mediated cleavage of endoglin could decrease soluble endoglin production, ameliorating clinical disease. However, experimental MMP-14 inhibition alone only partially repressed soluble endoglin production, implying other proteases might have a role in producing soluble endoglin. Here we investigated whether MMP-15-phylogenetically the closest MMP relative to MMP-14 with 66% sequence similarity-also cleaves endoglin to produce soluble endoglin. MMP-15 was localized to the syncytiotrophoblast layer of the placenta, the same site where endoglin was localized. Interestingly, it was significantly (p = 0.03) up-regulated in placentas from severe early-onset preeclamptic pregnancies (n = 8) compared to gestationally matched preterm controls (n = 8). However, siRNA knockdown of MMP-15 yielded no significant decrease of soluble endoglin production from either HUVECs or syncytialised BeWo cells in vitro. Importantly, concurrent siRNA knockdown of both MMP-14 and MMP-15 in HUVECS did not yield further decrease in soluble endoglin production compared to MMP-14 siRNA alone. We conclude MMP-15 is up-regulated in preeclampsia, but does not cleave endoglin to produce soluble endoglin. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
213. Neutrophil depletion retards endometrial repair in a mouse model.
- Author
-
Kaitu'u-Lino, Tu'uhevaha, Morison, Naomi, and Salamonsen, Lois
- Subjects
- *
NEUTROPHILS , *ENDOMETRIUM , *MENSTRUATION , *CELLS , *PROGESTERONE - Abstract
The contribution of the high abundance of inflammatory cells present in the human endometrium prior to and during menstruation is unknown with respect to endometrial repair and/or menstruation. In this study, the presence and localisation of markers for key inflammatory cells have been examined in a mouse model of endometrial breakdown and repair and the functional contribution of neutrophils has been determined. In the model, decidualisation is artificially induced and progesterone support withdrawn; the endometrial tissue progressively breaks down by 24 h after progesterone withdrawal and, by 48 h, has usually undergone complete repair. Neutrophils have been identified in low abundance in decidual tissue, rise in number during breakdown and are most abundant during early repair. Macrophages are barely detectable during breakdown or repair in this model, whereas uterine natural killer cells are found only in intact decidua. The functional contribution of neutrophils to endometrial breakdown and repair has been assessed via neutrophil depletion by using the antibody RB6-8C5. This antibody significantly depletes neutrophils from the circulation and tissue, affects endometrial breakdown and markedly delays endometrial repair. This study has therefore demonstrated that neutrophils are the most abundant leucocyte in this model and that they play an important functional role in the processes of endometrial breakdown and repair. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
214. Trophoblast Side-Population Markers are Dysregulated in Preeclampsia and Fetal Growth Restriction.
- Author
-
Wong, Georgia P., Hartmann, Sunhild, Simmons, David G., Ellis, Sarah, Nonn, Olivia, Cannon, Ping, Nguyen, Tuong-Vi, Nguyen, Anna, Bartho, Lucy A., Tong, Stephen, Hannan, Natalie J., and Kaitu'u-Lino, Tu'uhevaha J.
- Subjects
- *
FETAL growth retardation , *FETAL growth disorders , *HUMAN stem cells , *TROPHOBLAST , *BASAL lamina , *PROGENITOR cells - Abstract
Dysregulated progenitor cell populations may contribute to poor placental development and placental insufficiency pathogenesis. Side-population cells possess progenitor properties. Recent human trophoblast side-population isolation identified enrichment of 8 specific genes (CXCL8, ELL2, GATA6, HK2, HLA-DPB1, INTS6, SERPINE3 and UPP1) (Gamage et al. 2020, Stem Cell Rev Rep). We characterised these trophoblast side-population markers in human placenta and in placental insufficiency disorders: preeclampsia and fetal growth restriction (FGR). Trophoblast side-population markers localised to mononuclear trophoblasts lining the placental villous basement membrane in preterm control, preeclamptic and FGR placental sections (n = 3, panel of 3 markers/serial section). Analysis of single-cell transcriptomics of an organoid human trophoblast stem cell (hTSC) to extravillous trophoblast (EVT) differentiation model (Shannon et al. 2022, Development) identified that all side-population genes were enriched in mononuclear trophoblast and trophoblasts committed to differentiation under hTSC culture conditions. In vitro validation via 96 h time course hTSC differentiation to EVTs or syncytiotrophoblasts (n = 5) demonstrated ELL2 and HK2 increased with differentiation (p < 0.0024, p < 0.0039 respectively). CXCL8 and HLA-DPB1 were downregulated (p < 0.030, p < 0.011 respectively). GATA6 and INTS6 increased with EVT differentiation only, and UPP1 reduced with syncytialisation. SERPINE3 was undetectable. Trophoblast side-population marker mRNA was measured in human placentas (< 34-weeks' gestation; n = 78 preeclampsia, n = 30 FGR, and n = 18 gestation-matched controls). ELL2, HK2 and CXCL8 were elevated in preeclamptic (p = 0.0006, p < 0.0001, p = 0.0335 respectively) and FGR placentas (p = 0.0065, p < 0.0001, p = 0.0001 respectively) versus controls. Placental GATA6 was reduced in pregnancies with preeclampsia and FGR (p = 0.0014, p = 0.0146 respectively). Placental INTS6 was reduced with FGR only (p < 0.0001). This study identified the localisation of a unique trophoblast subset enriched for side-population markers. Aberrant expression of some side-population markers may indicate disruptions to unique trophoblast subtypes in placental insufficiency. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
215. Extracellular Matrix Dynamics in Scar-Free Endometrial Repair: Perspectives from Mouse In Vivo and Human In Vitro Studies1
- Author
-
Evans, Jemma, Kaitu'u-Lino, Tu'uhevaha, and Salamonsen, Lois A.
- Abstract
Repairof the postmenstrual endometrium presents a unique opportunity to examine nonscarring repair in an adult tissue. We aimed to characterize and determine the importance of extracellular matrix (ECM) dynamics in cell migration during endometrial repair. Utilizing an in vivo mouse model of postmenstrual repair and an in vitro model of human endometrial re-epithelialization, we determined the dynamic changes in expression of ECM and related factors in both models by array analysis of repairing areas. We also validated expression of integrins, growth factors, protease inhibitors, basement membrane, and adhesion molecules in vitro and in both mouse and human repairing endometrium by quantitative RT-PCR and immunohistochemical studies. Finally, we determined the functional importance of integrin–fibronectin interactions and matrix metalloprotease (MMP)-facilitated cell movement during re-epithelialization and propose a model for cell locomotion during postmenstrual repair. These data demonstrated the dynamic expression and functional importance of ECM interactions in endometrial repair, which may be important for scar-free repair.
- Published
- 2011
- Full Text
- View/download PDF
216. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
- Author
-
MacDonald, Teresa M., Tran, Chuong, Kaitu’u-Lino, Tu’uhevaha J., Brennecke, Shaun P., Hiscock, Richard J., Hui, Lisa, Dane, Kirsten M., Middleton, Anna L., Cannon, Ping, Walker, Susan P., Tong, Stephen, and Kaitu'u-Lino, Tu'uhevaha J
- Subjects
FETAL development ,GESTATIONAL age ,PREECLAMPSIA ,PLACENTAL growth factor ,PREECLAMPSIA diagnosis - Abstract
Background: Fetal growth restriction is a disorder of placental dysfunction with three to four-fold increased risk of stillbirth. Fetal growth restriction has pathophysiological features in common with preeclampsia. We hypothesised that angiogenesis-related factors in maternal plasma, known to predict preeclampsia, may also detect fetal growth restriction at 36 weeks' gestation. We therefore set out to determine the diagnostic performance of soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor (PlGF), and the sFlt-1:PlGF ratio, measured at 36 weeks' gestation, in identifying women who subsequently give birth to small-for-gestational-age (SGA; birthweight <10th centile) infants. We also aimed to validate the predictive performance of the analytes for late-onset preeclampsia in a large independent, prospective cohort.Methods: A nested 1:2 case-control study was performed including 102 cases of SGA infants and a matched group of 207 controls; and 39 cases of preeclampsia. We determined the diagnostic performance of each angiogenesis-related factor, and of their ratio, to detect SGA infants or preeclampsia, for a predetermined 10% false positive rate.Results: Median plasma levels of PlGF at 36 weeks' gestation were significantly lower in women who subsequently had SGA newborns (178.5 pg/ml) compared to normal birthweight controls (326.7 pg/ml, p < 0.0001). sFlt-1 was also higher among SGA cases, but this was not significant after women with concurrent preeclampsia were excluded. The sensitivity of PlGF to predict SGA infants was 28.8% for a 10% false positive rate. The sFlt-1:PlGF ratio demonstrated better sensitivity for preeclampsia than either analyte alone, detecting 69.2% of cases for a 10% false positive rate.Conclusions: Plasma PlGF at 36 weeks' gestation is significantly lower in women who subsequently deliver a SGA infant. While the sensitivity and specificity of PlGF currently limit clinical translation, our findings support a blood-based biomarker approach to detect late-onset fetal growth restriction. Thirty-six week sFlt-1:PlGF ratio predicts 69.2% of preeclampsia cases, and could be a useful screening test to triage antenatal surveillance. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
217. The Secrets of Women's Business.
- Author
-
KAITU'U-LINO, TU'UHEVAHA
- Abstract
The article focuses on the study conducted regarding endometrial repair following menstrual cycle. It explained that menstrual bleeding is the shedding of the endometrium that takes place after failure of fertilization. The researchers were able to study this mechanism by inducing menstruation in mice. The study concludes that cessation of bleeding is the hallmark of complete endometrial repair and healing errors leads to bleeding problems which is suffered by women worldwide.
- Published
- 2008
218. Screening circulating proteins to identify biomarkers of fetal macrosomia.
- Author
-
Cruickshank, Tess, Kaitu'u-Lino, Tu'uhevaha J., Cannon, Ping, Harper, Alesia, Nguyen, Tuong-Vi, Dane, Kirsten M., Middleton, Anna L., Kyritsis, Valerie P., Hastie, Roxanne, Tong, Stephen, Walker, Susan P., and MacDonald, Teresa M.
- Subjects
- *
FETAL macrosomia , *SHOULDER dystocia , *BLOOD collection , *PERINATAL death , *GESTATIONAL age , *PROTEINS - Abstract
Objective: Fetal macrosomia is a major risk factor for shoulder dystocia, which can lead to birth asphyxia, maternal and neonatal traumatic injuries, and perinatal death. If macrosomia is diagnosed in the antenatal period, labour can be induced to decrease shoulder dystocia. But current clinical methods to diagnose fetal macrosomia antenatally perform with poor accuracy. Therefore, improved methods to accurately diagnose fetal macrosomia are required. Blood biomarkers that predict fetal macrosomia could be one such novel diagnostic strategy. We undertook a nested case–control study from a prospective collection of 1000 blood samples collected at 36 weeks' gestation. We analysed plasma samples from 52 women who subsequently delivered a macrosomic (> 95th centile for gestational age) infant and 106 controls. Circulating concentrations of the proteins COBLL1, CSH1, HSD3B1, EGFL6, XAGE3, S100P, PAPPA-1, ERBB2 were assessed for their ability to predict macrosomic infants. Results: We did not identify any significant changes in the plasma concentrations of COBLL1, CSH1, HSD3B1, EGFL6, XAGE3, S100P, PAPPA-1, ERBB2 from women who subsequently delivered macrosomic neonates relative to control samples. Although we have not identified any potential biomarkers of fetal macrosomia, we have ruled out these particular eight protein candidates. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
219. Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin.
- Author
-
Whigham, Carole-Anne, MacDonald, Teresa M., Walker, Susan P., Pritchard, Natasha, Hannan, Natalie J., Cannon, Ping, Nguyen, Tuong Vi, Hastie, Roxanne, Tong, Stephen, and Kaitu'u-Lino, Tu'uhevaha J.
- Abstract
Preeclampsia is a pregnancy complication associated with elevated placental secretion of anti-angiogenic factors, maternal endothelial dysfunction and organ injury. GATA2 is a transcription factor expressed in the endothelium which regulates vascular homeostasis by controlling transcription of genes and microRNAs, including endothelial miR126. We assessed GATA2 and miR126 in preeclampsia. Whole blood circulating GATA2 mRNA and miR126 expression were significantly decreased in women with established early-onset preeclampsia compared to gestation-matched controls (p = 0.002, p < 0.0001, respectively). Using case-control groups selected from a large prospective cohort, whole blood circulating GATA2 mRNA at both 28 and 36 weeks' gestation was significantly reduced prior to the clinical diagnosis of preeclampsia (p = 0.012, p = 0.015 respectively). There were no differences in GATA2 mRNA or protein expression in preeclamptic placentas compared to controls, suggesting the placenta is an unlikely source. Inducing endothelial dysfunction in vitro by administering either tumour necrosis factor-α or placenta-conditioned media to endothelial cells, significantly reduced GATA2 mRNA expression (p < 0.0001), suggesting the reduced levels of circulating GATA2 mRNA may be of endothelial origin. Circulating GATA2 mRNA is decreased in women with established preeclampsia and decreased up to 12 weeks preceding onset of disease. Circulating mRNAs of endothelial origin may be a novel source of biomarker discovery for preeclampsia. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
220. 131. EGFR and the mitochondria; two parallel pathways regulating sFLT-1 secretion from placenta.
- Author
-
Kaitu'U-Lino, Tu'Uhevaha, Hastie, Roxanne, Brownfoot, Fiona, Cannon, Ping, Nguyen, Tuong-Vi, Hannan, Natalie, and Tong, Stephen
- Abstract
Introduction Although discovered more than a decade ago, the molecular pathways regulating sFLT-1 release in preeclampsia are still poorly understood. We have discovered the EGFR superhighway and the mitochondria (either via inhibiting the electron transport chain (ETC) or increasing molecules associated with mitochondrial biogenesis) independently regulate sFLT-1 secretion from placenta. The aim of this study was to assess whether targeting both pathways simultaneously additively reduced sFLT-1. Methods Isolated primary trophoblast were used for all studies. Metformin is a mitochondrial ETC inhibitor and resveratrol stimulates expression of mitochondrial biogenesis molecules SIRT1, AMPK and PGC1a. We initially assessed their effects on EGFR expression and activation using western blot. Gefitinib is an EGFR inhibitor, PD98059 a MEK-1 inhibitor and AG490 a STAT3 inhibitor (pathways downstream of the EGFR). We assessed their effects on mitochondrial respiration using a seahorse flux analyser. Having identified molecules that were either "EGFR-specific" or "Mitochondrial specific" we subsequently treated primary trophoblast simultaneously with drugs targeting both pathways and measured the effect on sFLT-1 secretion. Results Treatment of primary trophoblast with metformin or resveratrol significantly reduced sFLT-1 secretion and increased down-stream mitochondrial biogenesis molecules but had no significant effect on EGFR, pEGFR or downstream adaptor molecules ERK, pERK, STAT-3 or pSTAT-3. Although inhibitors targeting the EGFR super-highway also significantly reduced sFLT-1 secretion, none significantly altered mitochondrial respiration, or ATP production. When we targeted the two pathways simultaneously (combining gefitinib and metformin, gefitinib and resveratrol, metformin and PD980 or metformin and AG490) we found the reduction in sFLT-1 was additive compared to targeting either pathway alone. Conclusions Our study identifies EGFR signalling and the mitochondria as two parallel pathways that both regulate sFLT-1 secretion and which, when targeted simultaneously, can additively reduce sFLT-1. These pathways provide new therapeutic targets to reduce excess sFLT-1 secretion in pathological conditions and improve vascular homeostasis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
221. Paternal Expressed Gene 10 (PEG10) is decreased in early-onset preeclampsia.
- Author
-
Baird, Lydia, Cannon, Ping, Kandel, Manju, Nguyen, Tuong-Vi, Nguyen, Anna, Wong, Georgia, Murphy, Cíara, Brownfoot, Fiona C., Kadife, Elif, Hannan, Natalie J., Tong, Stephen, Bartho, Lucy A., and Kaitu'u-Lino, Tu'uhevaha J.
- Subjects
- *
GENE expression , *PREECLAMPSIA , *PREGNANCY complications , *HUMAN stem cells , *IMMUNOSTAINING - Abstract
Background: Preeclampsia is a severe complication of pregnancy which is attributed to placental dysfunction. The retrotransposon, Paternal Expressed Gene 10 (PEG10) harbours critical placental functions pertaining to placental trophoblast cells. Limited evidence exists on whether PEG10 is involved in preeclampsia pathogenesis. This study characterised the expression and regulation of PEG10 in placentas from patients with early-onset preeclampsia compared to gestation-matched controls. Methods: PEG10 expression was measured in plasma and placentas collected from patients with early-onset preeclampsia (< 34 weeks') and gestation-matched controls using ELISA (protein) and RT-qPCR (mRNA). First-trimester human trophoblast stem cells (hTSCs) were used for in vitro studies. PEG10 expression was measured during hTSC differentiation and hTSC exposure to hypoxia (1% O2) and inflammatory cytokines (IL-6 and TNFα) using RT-qPCR. Functional studies used PEG10 siRNA to measure the effect of reduced PEG10 on canonical TGF- β signalling and proliferation using luciferase and xCELLigence assays, respectively. Results: PEG10 mRNA expression was significantly reduced in placentas from patients with early-onset preeclampsia (< 34 weeks' gestation) relative to controls (p = 0.04, n = 78 vs n = 18 controls). PEG10 protein expression was also reduced in preeclamptic placentas (p = 0.03, n = 5 vs n = 5 controls, blinded assessment of immunohistochemical staining), but neither PEG10 mRNA nor protein could be detected in maternal circulation. PEG10 was most highly expressed in hTSCs, and its expression was reduced as hTSCs differentiated into syncytiotrophoblasts (p < 0.0001) and extravillous trophoblasts (p < 0.001). Trophoblast differentiation was not altered when hTSCs were treated with PEG10 siRNA (n = 5 vs n = 5 controls). PEG10 was significantly reduced in hTSCs exposed to hypoxia (p < 0.01). PEG10 was also reduced in hTSCs treated with the inflammatory cytokine TNF α (p < 0.01), but not IL-6. PEG10 knocked down (siRNA) in hTSCs showed reduced activation of the canonical TGF-β signalling effector, the SMAD binding element (p < 0.05) relative to controls. PEG10 knockdown in hTSCs however was not associated with any significant alterations in proliferation. Conclusions: Placental PEG10 is reduced in patients with early-onset preeclampsia. In vitro studies suggest that hypoxia and inflammation may contribute to PEG10 downregulation. Reduced PEG10 alters canonical TGF- β signalling, and thus may be involved in trophoblast dysfunction associated with this pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
222. Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth.
- Author
-
Arman, Bridget M., Binder, Natalie K., de Alwis, Natasha, Beard, Sally, Debruin, Danielle A., Hayes, Alan, Tong, Stephen, Kaitu'u-Lino, Tu'uhevaha J., and Hannan, Natalie J.
- Subjects
- *
PREMATURE labor , *UTERINE contraction , *ANIMAL models in research , *NIFEDIPINE , *CALCIUM channels , *PROTEIN expression - Abstract
Spontaneous preterm birth is the leading cause of perinatal morbidity and mortality. Tocolytics are drugs used in cases of imminent preterm birth to inhibit uterine contractions. Nifedipine is a calcium channel blocking agent used to delay threatened spontaneous preterm birth, however, has limited efficacy and lacks preclinical data regarding mechanisms of action. It is unknown if nifedipine affects the pro-inflammatory environment associated with preterm labour pathophysiology and we hypothesise nifedipine only targets myometrial contraction rather than also mitigating inflammation. We assessed anti-inflammatory and anti-contractile effects of nifedipine on human myometrium using in vitro and ex vivo techniques, and a mouse model of preterm birth. We show that nifedipine treatment inhibited contractions in myometrial in vitro contraction assays (P = 0.004 vs. vehicle control) and potently blocked spontaneous and oxytocin-induced contractions in ex vivo myometrial tissue in muscle myography studies (P = 0.01 vs. baseline). Nifedipine treatment did not reduce gene expression or protein secretion of pro-inflammatory cytokines in either cultured myometrial cells or ex vivo tissues. Although nifedipine could delay preterm birth in some mice, this was not consistent in all dams and was overall not statistically significant. Our data suggests nifedipine does not modulate preterm birth via inflammatory pathways in the myometrium, and this may account for its limited clinical efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
223. Investigating the Effects of Atrial Natriuretic Peptide on the Maternal Endothelium to Determine Potential Implications for Preeclampsia.
- Author
-
Binder, Natalie K., Beard, Sally, de Alwis, Natasha, Fato, Bianca R., Nguyen, Tuong-Vi, Kaitu'u-Lino, Tu'uhevaha J., and Hannan, Natalie J.
- Subjects
- *
ATRIAL natriuretic peptides , *PREECLAMPSIA , *ENDOTHELIUM , *ENDOTHELIUM diseases , *ENDOTHELIAL cells , *CARDIOVASCULAR diseases - Abstract
Preeclampsia is associated with an increased lifelong risk of cardiovascular disease (CVD). It is not clear whether this is induced by persistent systemic organ and vascular damage following preeclampsia or due to a predisposition to both conditions that share cardiovascular pathophysiology. Common to both CVD and preeclampsia is the dysregulation of corin and its proteolytic product, atrial natriuretic peptide (ANP). ANP, a hypotensive hormone converted from pro-ANP by corin, is involved in blood pressure homeostasis. While corin is predominantly a cardiac enzyme, both corin and pro-ANP are significantly upregulated in the gravid uterus and dysregulated in preeclampsia. Relatively little is known about ANP function in the endothelium during a pregnancy complicated by preeclampsia. Here, we investigated the effect of ANP on endothelial cell proliferation and migration, markers of endothelial dysfunction, and receptor expression in omental arteries exposed to circulating preeclamptic toxins. ANP receptor expression is significantly upregulated in preeclamptic vasculature but not because of exposure to preeclampsia toxins tumour necrosis factor α or soluble fms-like tyrosine kinase-1. The supplementation of endothelial cells with ANP did not promote proliferation or migration, nor did ANP improve markers of endothelial dysfunction. The role of ANP in preeclampsia is unlikely to be via endothelial pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
224. Claudin-11 expression and localisation is regulated by androgens in rat Sertoli cells in vitro.
- Author
-
Kaitu'u-Lino, Tu'uhevaha J., Sluka, Pavel, Foo, Caroline F. H., and Stanton, Peter G.
- Subjects
PROTEINS ,SERTOLI cells ,TIGHT junctions ,TESTIS ,TESTOSTERONE ,FOLLICLE-stimulating hormone ,PHYSIOLOGICAL control systems ,ANDROGENS - Abstract
Claudin-11 and occludin are protein components in tight junctions (TJs) between Sertoli cells which are important for the maintenance of the blood-testis barrier. Barrier formation occurs during puberty, with evidence suggesting hormonal regulation of both claudin-11 and occludin. This study aimed to investigate the regulation of claudin-11 and occludin mRNA expression by testosterone (T) and FSH and their immunolocalisation at rat Sertoli cell TJs in vitro, and to correlate any steroid regulation with the functional capacity of TJs. Sertoli cells formed functional TJs within 3 days as assessed by transepithelial electrical resistance (TER). Both T and dihydrotestosterone significantly (P < 0.01) increased TER twofold and claudin-11 mRNA two- to threefold within 3 days. FSH partially stimulated TER and claudin-11 mRNA, but estradiol had no effect. T also promoted claudin-11 localisation into extensive intercellular contacts. In contrast to claudin-11, Tand FSH did not change occludin mRNA expression, however, T promoted localisation of occludin at cell contacts in a similar manner to claudin-11. Addition of flutamide to T-stimulated cells caused a twofold decrease in both TER and claudin-11 mRNA expression, and resulted in the loss of both proteins from cell contacts. This effect was reversible following flutamide removal. It is concluded that androgens i) co-regulate claudin-11 mRNA expression and TER, implicating claudin-11 in TJ formation and ii) promote the localisation of claudin-11 and occludin at Sertoli cell contacts. Hence, the ability of androgens to maintain spermatogenesis in vivo is partly via their effects on TJ proteins and regulation of the blood-testis barrier. [ABSTRACT FROM AUTHOR]
- Published
- 2007
225. Endothelial protein C receptor is increased in preterm preeclampsia and fetal growth restriction.
- Author
-
Andres, Faith, Hannan, Natalie J., Walker, Susan P., MacDonald, Teresa M., Wong, Georgia P., Murphy, Ciara, Cannon, Ping, Kandel, Manju, Masci, Joshua, Nguyen, Tuong‐Vi, Abboud, Alison, Idzes, Danica, Kyritsis, Valerie, Pritchard, Natasha, Tong, Stephen, and Kaitu'u‐Lino, Tu'uhevaha J.
- Abstract
Placental dysfunction is the leading cause of both preeclampsia and fetal growth restriction. This study aimed to characterize endothelial protein C receptor (EPCR) in preterm preeclampsia, term preeclampsia, and fetal growth restriction (defined by delivery of a small for gestational age [SGA] infant [<10% birthweight centile]) and examine its regulation in primary syncytiotrophoblast. Placental EPCR mRNA and protein were significantly increased in patients with preterm preeclampsia (<34 weeks gestation) compared to gestation‐matched controls (p <.0001). In the plasma, EPCR was also significantly elevated (p =.01) in established preterm preeclampsia while its substrate, protein C (PC) was significantly reduced (p =.0083). Placentas from preterm small for gestational age (SGA) cases, had elevated EPCR mRNA expression (p <.0001) relative to controls. At 36 weeks, no significant changes in plasma EPCR were detected in samples from patients destined to develop preeclampsia or deliver an SGA infant at term. In terms of syncytiotrophoblast, hypoxia significantly increased EPCR mRNA expression (p =.008), but Tumor Necrosis Factor Alpha (TNF‐α) decreased EPCR mRNA. Interleukin‐6 (IL‐6) had no significant effect on EPCR mRNA expression. When isolated syncytiotrophoblast was treated with metformin under hypoxia (1% O2) or normoxia (8% O2), EPCR mRNA expression was significantly reduced (p =.008) relative to control. In conclusion, EPCR is markedly elevated in the placenta and the circulation of patients with established preterm preeclampsia and placental increases may be associated with hypoxia. Additionally, fetal growth‐restricted pregnancies (as defined by the delivery of an SGA infant) also demonstrated elevated placental EPCR. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
226. Serum Collected from Preeclamptic Pregnancies Drives Vasoconstriction of Human Omental Arteries—A Novel Ex Vivo Model of Preeclampsia for Therapeutic Development.
- Author
-
Fato, Bianca R., de Alwis, Natasha, Beard, Sally, Binder, Natalie K., Pritchard, Natasha, Tong, Stephen, Kaitu'u-Lino, Tu'uhevaha J., and Hannan, Natalie J.
- Subjects
- *
PREECLAMPSIA , *VASOCONSTRICTION , *ENDOTHELIUM diseases , *ARTERIES , *PREGNANCY , *CESAREAN section - Abstract
New-onset maternal hypertension is a hallmark of preeclampsia, driven by widespread endothelial dysfunction and systemic vasoconstriction. Here, we set out to create a new ex vivo model using preeclamptic serum to cause injury to the endothelium, mimicking vascular dysfunction in preeclampsia and offering the potential to evaluate candidate therapeutic interventions. Human omental arteries were collected at caesarean section from normotensive pregnant patients at term (n = 9). Serum was collected from pregnancies complicated by preterm preeclampsia (birth < 34 weeks' gestation, n = 16), term preeclampsia (birth > 37 weeks' gestation, n = 5), and healthy gestation-matched controls (preterm n = 16, term n = 12). Using wire myography, we performed ex vivo whole vessel assessment where human omental arteries were treated with increasing doses of each serum treatment (2–20%) and vasoreactivity was assessed. All pregnant serum treatments successfully drove vasoconstriction; no significant difference was observed in the degree of vasoconstriction when exposed to preeclamptic or control serum. We further demonstrated the ability of esomeprazole (a candidate therapeutic for preeclampsia; 0.1–100 µM) to drive vasorelaxation of pre-constricted vessels (only with serum from preeclamptic patients). In summary, we describe a novel human physiological model of preeclamptic vascular constriction. We demonstrate its exciting potential to screen drugs for their therapeutic potential as treatment for vasoconstriction induced by preeclampsia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
227. Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease.
- Author
-
de Alwis, Natasha, Fato, Bianca R., Beard, Sally, Binder, Natalie K., Kaitu'u-Lino, Tu'uhevaha J., Onda, Kenji, and Hannan, Natalie J.
- Subjects
- *
PREECLAMPSIA , *PROTON pump inhibitors , *ESOMEPRAZOLE , *VASCULAR cell adhesion molecule-1 , *ANIMAL models in research , *REACTIVE oxygen species - Abstract
Previously, we demonstrated that the proton pump inhibitor, esomeprazole magnesium hydrate (MH), could have potential as a repurposed treatment against preeclampsia, a serious obstetric condition. In this study we investigate the difference in the preclinical effectiveness between 100 µM of esomeprazole MH and its hydration isomer, esomeprazole magnesium trihydrate (MTH). Here, we found that both treatments reduced secretion of sFLT-1 (anti-angiogenic factor) from primary cytotrophoblast, but only esomeprazole MH reduced sFLT-1 secretion from primary human umbilical vein endothelial cells (assessed via ELISA). Both drugs could mitigate expression of the endothelial dysfunction markers, vascular cell adhesion molecule-1 and endothelin-1 (via qPCR). Neither esomeprazole MH nor MTH quenched cytotrophoblast reactive oxygen species production in response to sodium azide (ROS assay). Finally, using wire myography, we demonstrated that both compounds were able to induce vasodilation of human omental arteries at 100 µM. Esomeprazole is safe to use in pregnancy and a candidate treatment for preeclampsia. Using primary human tissues and cells, we validated that esomeprazole is effective in enhancing vascular relaxation, and can reduce key factors associated with preeclampsia, including sFLT-1 and endothelial dysfunction. However, esomeprazole MH was more efficacious than esomeprazole MTH in our in vitro studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
228. Actions of Esomeprazole on the Maternal Vasculature in Lean and Obese Pregnant Mice with Impaired Nitric Oxide Synthesis: A Model of Preeclampsia.
- Author
-
de Alwis, Natasha, Binder, Natalie K., Mangwiro, Yeukai T. M., Beard, Sally, Pritchard, Natasha, Kadife, Elif, Fato, Bianca R., Keenan, Emerson, Brownfoot, Fiona C., Kaitu'u-Lino, Tu'uhevaha J., and Hannan, Natalie J.
- Subjects
- *
PREECLAMPSIA , *NITRIC oxide , *ESOMEPRAZOLE , *NITRIC-oxide synthases , *BLOOD pressure , *PROTON pump inhibitors - Abstract
Preeclampsia is a devastating, multisystem disorder of pregnancy. It has no cure except delivery, which if premature can impart significant neonatal morbidity. Efforts to repurpose pregnancy-safe therapeutics for the treatment of preeclampsia have led to the assessment of the proton pump inhibitor, esomeprazole. Preclinically, esomeprazole reduced placental secretion of anti-angiogenic sFlt-1, improved endothelial dysfunction, promoted vasorelaxation, and reduced maternal hypertension in a mouse model. Our understanding of the precise mechanisms through which esomeprazole works to reduce endothelial dysfunction and enhance vasoreactivity is limited. Evidence from earlier studies suggested esomeprazole might work via the nitric oxide pathway, upregulating endothelial nitric oxide synthase (eNOS). Here, we investigated the effect of esomeprazole in a mouse model of L-NAME-induced hypertension (decreased eNOS activity). We further antagonised the model by addition of diet-induced obesity, which is relevant to both preeclampsia and the nitric oxide pathway. Esomeprazole did not decrease blood pressure in this model, nor were there any alterations in vasoreactivity or changes in foetal outcomes in lean mice. We observed similar findings in the obese mouse cohort, except esomeprazole treatment enhanced ex vivo acetylcholine-induced vasorelaxation. As acetylcholine induces nitric oxide production, these findings hint at a function for esomeprazole in the nitric oxide pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
229. NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast.
- Author
-
de Alwis, Natasha, Beard, Sally, Binder, Natalie K., Pritchard, Natasha, Kaitu'u-Lino, Tu'uhevaha J., Walker, Susan P., Stock, Owen, Groom, Katie M., Petersen, Scott, Henry, Amanda, Said, Joanne M., Seeho, Sean, Kane, Stefan C., Tong, Stephen, and Hannan, Natalie J.
- Subjects
- *
GENE expression , *PLACENTAL growth factor , *PREECLAMPSIA , *FETAL growth retardation , *PLACENTA , *PROTEIN expression - Abstract
Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2) transcripts are elevated in the circulation of individuals whose pregnancies are complicated by preterm fetal growth restriction (FGR). In this paper, we show that the cases with preeclampsia (PE) have increased circulating NR4A2 transcripts compared to those with normotensive FGR. We aimed to establish whether the dysfunctional placenta mirrors the increase in NR4A2 transcripts and further, to uncover the function of placental NR4A2. NR4A2 expression was detected in preterm and term placental tissue; expressed higher at term. NR4A2 mRNA expression and protein were not altered in placentas from preterm FGR or PE pregnancies. Hypoxia (1% O2 compared to 8% O2) significantly reduced cytotrophoblast NR4A2 mRNA expression, but not placental explant NR4A2 expression. Silencing cytotrophoblast NR4A2 expression under hypoxia (via short interfering (si)RNAs) did not alter angiogenic Placental Growth Factor, nor anti-angiogenic sFlt-1 mRNA expression or protein secretion, but increased expression of cellular antioxidant, oxidative stress, inflammatory, and growth genes. NR4A2 expression was also not altered in a model of tumour necrosis factor-α-induced endothelial dysfunction, or with pravastatin treatment. Further studies are required to identify the origin of the circulating transcripts in pathological pregnancies, and investigate the function of placental NR4A2. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
230. Circulating trace elements for the prediction of preeclampsia and small for gestational age babies.
- Author
-
McKeating, Daniel R., Fisher, Joshua J., MacDonald, Teresa, Walker, Sue, Tong, Stephen, Bennett, William W., Kaitu'u-Lino, Tu'uhevaha J., and Perkins, Anthony V.
- Subjects
- *
SMALL for gestational age , *PREECLAMPSIA , *INFANTS , *MOTHER-child relationship , *BLOOD plasma , *MASS spectrometers - Abstract
Introduction: Poor gestational outcomes due to placental insufficiency can have lifelong consequences for mother and child. Objective: There is a need for better methods of diagnosis, and elemental metabolomics may provide a means to determine the risk of gestational disorders. Methods: This study used blood plasma samples collected at 36 weeks' gestation from women who later developed preeclampsia (n = 38), or small-for-gestational age babies (n = 91), along with matched controls (n = 193). Multi-element analysis was conducted by inductively coupled plasma mass spectrometer (ICP-MS), allowing simultaneous measurement of 28 elements. Results: Women who later developed PE, exhibited significantly increased concentrations of K, Rb and Ba. For SGA pregnancies, there was a significant increase in Cu and a decrease in As concentrations. Despite significant differences in single elements, the elemental profile of groups indicated no clustering of control, PE, or SGA samples. Positive predicative values correctly identified approximately 60% of SGA and 70% of PE samples. Conclusion: This is the first-time elemental metabolomics has been used to predict SGA and PE at 36 weeks. Though significant changes were identified, routine clinical use may be limited but may contribute to a multi marker test. Future analysis should include other biomarkers, metabolic data or clinical measurements made throughout gestation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
231. DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia.
- Author
-
de Alwis, Natasha, Beard, Sally, Binder, Natalie K., Pritchard, Natasha, Kaitu'u-Lino, Tu'uhevaha J., Walker, Susan P., Stock, Owen, Groom, Katie, Petersen, Scott, Henry, Amanda, Said, Joanne M., Seeho, Sean, Kane, Stefan C., Hui, Lisa, Tong, Stephen, and Hannan, Natalie J.
- Subjects
- *
HYPOXEMIA , *FETAL growth retardation , *PLACENTA , *PREGNANCY complications , *MESSENGER RNA - Abstract
Previously, we identified increased maternal circulating DAAM2 mRNA in pregnancies complicated by preterm fetal growth restriction (FGR). Here, we assessed whether circulating DAAM2 mRNA could detect FGR, and whether the DAAM2 gene, known to play roles in the Wnt signalling pathway is expressed in human placenta and associated with dysfunction and FGR. We performed linear regression analysis to calculate area under the ROC curve (AUC) for DAAM2 mRNA expression in the maternal circulation of pregnancies complicated by preterm FGR. DAAM2 mRNA expression was assessed across gestation by qPCR. DAAM2 protein and mRNA expression was assessed in preterm FGR placenta using western blot and qPCR. DAAM2 expression was assessed in term cytotrophoblasts and placental explant tissue cultured under hypoxic and normoxic conditions by qPCR. Small interfering RNAs were used to silence DAAM2 in term primary cytotrophoblasts. Expression of growth, apoptosis and oxidative stress genes were assessed by qPCR. Circulating DAAM2 mRNA was elevated in pregnancies complicated by preterm FGR [p < 0.0001, AUC = 0.83 (0.78–0.89)]. Placental DAAM2 mRNA was detectable across gestation, with highest expression at term. DAAM2 protein was increased in preterm FGR placentas but demonstrated no change in mRNA expression. DAAM2 mRNA expression was increased in cytotrophoblasts and placental explants under hypoxia. Silencing DAAM2 under hypoxia decreased expression of pro-survival gene, BCL2 and oxidative stress marker, NOX4, whilst increasing expression of antioxidant enzyme, HMOX-1. The increased DAAM2 associated with FGR and hypoxia implicates a potential role in placental dysfunction. Decreasing DAAM2 may have cytoprotective effects, but further research is required to elucidate its role in healthy and dysfunctional placentas. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
232. Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth.
- Author
-
Hannan, Natalie J., Stock, Owen, Spencer, Rebecca, Whitehead, Clare, David, Anna L., Groom, Katie, Petersen, Scott, Henry, Amanda, Said, Joanne M., Seeho, Sean, Kane, Stefan C., Gordon, Lavinia, Beard, Sally, Chindera, Kantaraja, Karegodar, Smita, Hiscock, Richard, Pritchard, Natasha, Kaitu'u-Lino, Tu'uhevaha J., Walker, Susan P., and Tong, Stephen
- Subjects
- *
STILLBIRTH , *FETAL development , *PREGNANCY , *PREGNANCY tests , *FETAL anoxia , *MESSENGER RNA - Abstract
Background: Fetuses affected by placental insufficiency do not receive adequate nutrients and oxygenation, become growth restricted and acidemic, and can demise. Preterm fetal growth restriction is a severe form of placental insufficiency with a high risk of stillbirth. We set out to identify maternal circulating mRNA transcripts that are differentially expressed in preterm pregnancies complicated by very severe placental insufficiency, in utero fetal acidemia, and are at very high risk of stillbirth.Methods: We performed a cohort study across six hospitals in Australia and New Zealand, prospectively collecting blood from 128 pregnancies complicated by preterm fetal growth restriction (delivery < 34 weeks' gestation) and 42 controls. RNA-sequencing was done on all samples to discover circulating mRNAs associated with preterm fetal growth restriction and fetal acidemia in utero. We used RT-PCR to validate the associations between five lead candidate biomarkers of placental insufficiency in an independent cohort from Europe (46 with preterm fetal growth restriction) and in a third cohort of pregnancies ending in stillbirth.Results: In the Australia and New Zealand cohort, we identified five mRNAs that were highly differentially expressed among pregnancies with preterm fetal growth restriction: NR4A2, EMP1, PGM5, SKIL, and UGT2B1. Combining three yielded an area under the receiver operative curve (AUC) of 0.95. Circulating NR4A2 and RCBTB2 in the maternal blood were dysregulated in the presence of fetal acidemia in utero. We validated the association between preterm fetal growth restriction and circulating EMP1, NR4A2, and PGM5 mRNA in a cohort from Europe. Combining EMP1 and PGM5 identified fetal growth restriction with an AUC of 0.92. Several of these genes were differentially expressed in the presence of ultrasound parameters that reflect placental insufficiency. Circulating NR4A2, EMP1, and RCBTB2 mRNA were differentially regulated in another cohort destined for stillbirth, compared to ongoing pregnancies. EMP1 mRNA appeared to have the most consistent association with placental insufficiency in all cohorts.Conclusions: Measuring circulating mRNA offers potential as a test to identify pregnancies with severe placental insufficiency and at very high risk of stillbirth. Circulating mRNA EMP1 may be promising as a biomarker of severe placental insufficiency. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
233. Can single-cell and spatial omics unravel the pathophysiology of pre-eclampsia?
- Author
-
Hartmann, Sunhild, Botha, Stefan Marc, Gray, Clive M., Valdes, Daniela S., Tong, Stephen, Kaitu'u-Lino, Tu'uhevaha J., Herse, Florian, Bergman, Lina, Cluver, Catherine A., Dechend, Ralf, and Nonn, Olivia
- Subjects
- *
ECLAMPSIA , *PREECLAMPSIA , *PATHOLOGICAL physiology , *CEREBRAL edema , *PULMONARY edema , *CEREBRAL ischemia - Abstract
Pre-eclampsia is a leading cause of maternal and fetal morbidity and mortality. Characterised by the onset of hypertension and proteinuria in the second half of pregnancy, it can lead to maternal end-organ injury such as cerebral ischemia and oedema, pulmonary oedema and renal failure, and potentially fatal outcomes for both mother and fetus. The causes of the different maternal end-organ phenotypes of pre-eclampsia and why some women develop pre-eclampsia condition early in pregnancy have yet to be elucidated. Omics methods include proteomics, genomics, metabolomics, transcriptomics. These omics techniques, previously mostly used on bulk tissue and individually, are increasingly available at a single cellular level and can be combined with each other. Multi-omics techniques on a single-cell or spatial level provide us with a powerful tool to understand the pathophysiology of pre-eclampsia. This review will explore the status of omics methods and how they can and could contribute to understanding the pathophysiology of pre-eclampsia. • The pathophysiology of pre-eclampsia and ist subtypes remains to be elucidated. • Various omics techniques are increasingly available on a single-cell and spatial level. • These novel techniques may help to better understand the pathophysiology of pre-eclampsia and its different phenotypes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
234. Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro.
- Author
-
Hastie, Roxanne, Tong, Stephen, Hannan, Natalie J., Brownfoot, Fiona, Cannon, Ping, and Kaitu’u-Lino, Tu’uhevaha J.
- Subjects
- *
ENDOTHELIUM diseases , *EPIDERMAL growth factor , *PREECLAMPSIA , *PEPTIDES , *TUMOR necrosis factors - Abstract
Preeclampsia is a hypertensive disorder of pregnancy, responsible for over 60 000 maternal deaths annually. Endothelial dysfunction is a central aspect to its pathophysiology, and currently, no medical therapeutic is available for its treatment. In this study, we aim to investigate the effect of epidermal growth factor (EGF) on endothelial dysfunction using primary human tissues. We performed a number of in vitro assays that mimic the vascular endothelial dysfunction that occurs in preeclampsia. Epidermal growth factor reduced the expression of vascular cell adhesion molecule-1, a marker of endothelial dysfunction, after insult with tumor necrosis factor α (TNF-α) or serum from women with preeclampsia. Additionally, after TNF-α insult, EGF reduced tube disruption and the adhesion of monocytes to primary human umbilical vein endothelial cells (HUVECs). Our findings suggest that EGF reduces endothelial dysfunction in primary HUVECs. Epidermal growth factor may have potential as a novel peptide treatment for preeclampsia and other diseases where there is endothelial dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
235. Senescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia.
- Author
-
Nonn O, Debnath O, Valdes DS, Sallinger K, Secener AK, Fischer C, Tiesmeyer S, Nimo J, Kuenzer T, Ulrich J, Maxian T, Knöfler M, Karau P, Bartolomaeus H, Kroneis T, Frolova A, Neuper L, Haase N, Malt A, Müller-Bötticher N, Kräker K, Kedziora S, Forstner D, Eils R, Schmidt-Ullrich R, Haider S, Verlohren S, Stern C, Sugulle M, Jones S, Thilaganathan B, Kaitu'u-Lino TJ, Tong S, Huppertz B, El-Heliebi A, Staff AC, Coscia F, Müller DN, Dechend R, Gauster M, Ishaque N, and Herse F
- Abstract
Background: Preeclampsia is a severe hypertensive disorder in pregnancy that causes preterm delivery, maternal and fetal morbidity, mortality, and life-long sequelae. Understanding the pathogenesis of preeclampsia is a critical first step toward protecting mother and child from this syndrome and increased risk of cardiovascular disease later in life. However, effective early predictive tests and therapies for preeclampsia are scarce., Methods: To identify novel markers and signaling pathways for early onset preeclampsia, we profiled human maternal-fetal interface units (fetal villi and maternal decidua) from early onset preeclampsia and healthy controls using single-nucleus RNA sequencing combined with spatial transcriptomics. The placental syncytiotrophoblast is in direct contact with maternal blood and forms the barrier between fetal and maternal circulation., Results: We identified different transcriptomic states of the endocrine syncytiotrophoblast nuclei with patterns of dysregulation associated with a senescence-associated secretory phenotype and a spatial dysregulation of senescence in the placental trophoblast layer. Elevated senescence markers were validated in placental tissues of clinical multicenter cohorts. Importantly, several secreted senescence-associated secretory phenotype factors were elevated in maternal blood already in the first trimester. We verified the secreted senescence markers, PAI-1 (plasminogen activator inhibitor 1) and activin A, as identified in our single-nucleus RNA sequencing model as predictive markers before clinical preeclampsia diagnosis., Conclusions: This indicates that increased syncytiotrophoblast senescence appears weeks before clinical manifestation of early onset preeclampsia, suggesting that the dysregulated preeclamptic placenta starts with higher cell maturation resulting in premature and increased senescence-associated secretory phenotype release. These senescence-associated secretory phenotype markers may serve as an additional early diagnostic tool for this syndrome.
- Published
- 2024
- Full Text
- View/download PDF
236. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) is reduced with preeclampsia and small for gestational aged fetuses.
- Author
-
Bartho LA, Walker SP, Cannon P, Nguyen TV, Nguyen A, Botha SM, Hannan NJ, Tong S, and Kaitu'u-Lino TJ
- Subjects
- Humans, Female, Pregnancy, Adult, Infant, Newborn, RNA, Messenger metabolism, Hypoxia metabolism, Pre-Eclampsia metabolism, Receptors, Immunologic metabolism, Receptors, Immunologic genetics, Placenta metabolism, Infant, Small for Gestational Age
- Abstract
Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) is an inhibitory receptor expressed on immune cells. We evaluated LAIR1 in placentas from preeclamptic or small for gestational age (SGA) pregnancies, and placental explant model (1 % O
2 , IL6 and TNFα, or control). LAIR1 mRNA was reduced in placentas from preeclamptic (p < 0.0001, n = 78) and SGA (p < 0.0001, n = 32) pregnancies. LAIR1 protein expression was reduced in placentas from preeclampsia (p < 0.0001, n = 43) and SGA (p = 0.009, n = 10) pregnancies. Hypoxia (1 % O2 ) reduced LAIR1 mRNA expression in placental explants (p = 0.008). These findings suggest hypoxia modulates LAIR1 expression in the placenta., Competing Interests: Declaration of competing Interest None., (Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
237. Exploring the Therapeutic Potential of C-Type Natriuretic Peptide for Preeclampsia.
- Author
-
Fato BR, de Alwis N, Beard S, Binder NK, Pritchard N, Kaitu'u-Lino TJ, Bubb KJ, and Hannan NJ
- Subjects
- Female, Humans, Pregnancy, Adult, Omentum blood supply, Vasoconstriction drug effects, Arteries drug effects, Arteries metabolism, Arteries physiopathology, Pre-Eclampsia physiopathology, Pre-Eclampsia metabolism, Pre-Eclampsia drug therapy, Natriuretic Peptide, C-Type pharmacology, Receptors, Atrial Natriuretic Factor genetics, Receptors, Atrial Natriuretic Factor metabolism, Vasodilation drug effects, Vasodilation physiology
- Abstract
Background: Preeclampsia is a serious condition of pregnancy, complicated by aberrant maternal vascular dysfunction. CNP (C-type natriuretic peptide) contributes to vascular homeostasis, acting through NPR-B (natriuretic peptide receptor-B) and NPR-C (natriuretic peptide receptor-C). CNP mitigates vascular dysfunction of arteries in nonpregnant cohorts; this study investigates whether CNP can dilate maternal arteries in ex vivo preeclampsia models., Methods: Human omental arteries were dissected from fat biopsies collected during cesarean section. CNP, NPR-B, and NPR-C mRNA expression was assessed in arteries collected from pregnancies complicated by preeclampsia (n=6) and normotensive controls (n=11). Using wire myography, we investigated the effects of CNP on dilation of arteries from normotensive pregnancies. Arteries were preconstricted with either serum from patients with preeclampsia (n=6) or recombinant ET-1 (endothelin-1; vasoconstrictor elevated in preeclampsia; n=6) to model vasoconstriction associated with preeclampsia. Preconstricted arteries were treated with recombinant CNP (0.001-100 µmol/L) or vehicle and vascular relaxation assessed. In further studies, arteries were preincubated with NPR-B (5 µmol/L) and NPR-C (10 µmol/L) antagonists before serum-induced constriction (n=4-5) to explore mechanistic signaling., Results: CNP, NPR-B, and NPR-C mRNAs were not differentially expressed in omental arteries from preeclamptic pregnancies. CNP potently stimulated maternal artery vasorelaxation in our model of preeclampsia (using preeclamptic serum). Its vasodilatory actions were driven through the activation of NPR-B predominantly; antagonism of this receptor alone dampened CNP vasorelaxation. Interestingly, CNP did not reduce ET-1-driven omental artery constriction., Conclusions: Collectively, these data suggest that enhancing CNP signaling through NPR-B offers a potential therapeutic strategy to reduce systemic vascular constriction in preeclampsia., Competing Interests: None.
- Published
- 2024
- Full Text
- View/download PDF
238. Plasma metabolites are altered before and after diagnosis of preeclampsia or fetal growth restriction.
- Author
-
Bartho LA, McKeating DR, Walker SP, Nijagal B, MacDonald TM, Pritchard N, Hannan NJ, Perkins AV, Tong S, and Kaitu'u-Lino TJ
- Subjects
- Humans, Female, Pregnancy, Adult, Prospective Studies, Metabolome, Biomarkers blood, Case-Control Studies, Pre-Eclampsia blood, Pre-Eclampsia diagnosis, Fetal Growth Retardation blood, Fetal Growth Retardation diagnosis, Metabolomics methods
- Abstract
Metabolomics is the study of small molecules (metabolites), within cells, tissues and biofluids. Maternal metabolites can provide important insight into the health and development of both mother and fetus throughout pregnancy. This study assessed metabolic profiles in the maternal circulation prior to and at the time of diagnosis of preeclampsia and fetal growth restriction. Maternal plasma samples were collected from two independent cohorts: (1) Established disease cohort: 50 participants diagnosed with early-onset preeclampsia (< 34 weeks' gestation), 14 with early-onset fetal growth restriction, and 25 gestation-matched controls. (2) Prospective cohort, collected at 36 weeks' gestation before diagnosis: 17 participants later developed preeclampsia, 49 delivered infants with fetal growth restriction (birthweight < 5th centile), and 72 randomly selected controls. Metabolic evaluation was performed by Metabolomics Australia on the Agilent 6545 QTOF Mass Spectrometer. In the established disease cohort, 77 metabolites were altered in circulation from participants with preeclampsia - increased L-cysteine (3.73-fold), L-cystine (3.28-fold), L-acetylcarnitine (2.57-fold), and carnitine (1.53-fold) (p < 0.05). There were 53 metabolites dysregulated in participants who delivered a fetal growth restriction infant-including increased levulinic acid, citric acid (1.93-fold), and creatine (1.14-fold) (p < 0.05). In the prospective cohort, 30 metabolites were altered in participants who later developed preeclampsia at term - reduced glutaric acid (0.85-fold), porphobilinogen (0.77-fold) and amininohippuric acid (0.82-fold) (p < 0.05) was observed. There were 5 metabolites altered in participants who later delivered a fetal growth restriction infant - including reduced 3-methoxybenzenepropanoic acid (p < 0.05). Downstream pathway analysis revealed aminoacyl-tRNA biosynthesis to be most significantly altered in the established cohort in preeclampsia (13/48 hits, p < 0.001) and fetal growth restriction (7/48 hits, p < 0.001). The predictive cohort showed no significant pathway alterations. This study observed altered metabolites in maternal plasma collected before and after diagnosis of a preeclampsia or fetal growth restriction. While a significant number of metabolites were altered with established disease, few changes were observed in the predictive cohort. Thus, metabolites measured in this study may not be useful as predictors of preeclampsia or fetal growth restriction., (© 2024. Crown.)
- Published
- 2024
- Full Text
- View/download PDF
239. Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial.
- Author
-
Cluver CA, Bergman L, Imberg H, Mol BW, Hall D, Bekker A, Gordon A, Brownfoot F, Kaitu'u-Lino TJ, Walker SP, and Tong S
- Subjects
- Humans, Pregnancy, Female, Double-Blind Method, South Africa, Hypoglycemic Agents therapeutic use, Infant, Newborn, Randomized Controlled Trials as Topic, Adult, Pregnancy Outcome, Metformin therapeutic use, Pre-Eclampsia prevention & control
- Abstract
Introduction: Preterm pre-eclampsia is a leading cause of maternal morbidity and mortality. The Pre-eclampsia Intervention 2 (PI 2) trial suggested that metformin sustained release (XR) may prolong gestation by a week in pregnant women undergoing expectant management (7.6 days, geometric mean ratio 1.39, 95% CI 0.99 to 1.95; p=0.057). These findings should be confirmed with a larger sample size, and we need to know if such a prolongation improves neonatal outcome. Here, we describe the protocol for such a follow-up trial., Methods: The PI 3 trial is a phase III, intention-to-treat, double-blind, placebo-controlled randomised clinical trial to assess if metformin XR can prolong gestation and improve neonatal outcomes in women undergoing expectant management for preterm pre-eclampsia. We will recruit women who are between 26+0 and 31+6 weeks pregnant. Women will be randomised to receive either 3 g metformin XR or an identical placebo in divided daily doses. The primary outcome is prolongation of pregnancy. Secondary outcomes are neonatal birth weight and length of neonatal care admission (an indicator of neonatal health at birth). All other outcomes will be exploratory. We will record tolerability and adverse events. We plan a sample size of 500 participants to be powered for the primary and secondary outcomes., Ethics and Dissemination: PI 3 has ethical approval (Health Research Ethics Committee 2, Stellenbosch University, Protocol number M21/03/007, Project ID 21639, Federal Wide Assurance Number 00001372, Institutional Review Board Number IRB0005239), and is registered with the Pan African Clinical Trial Registry (PACTR202104532026017) and the South African Medicine Control Council (20211211). Data will be presented at international conferences and published in peer-reviewed journals., Trial Registration Number: PACTR202104532026017)., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
240. Investigating ticagrelor in a preclinical pipeline as a novel therapeutic to prevent preterm birth.
- Author
-
Arman BM, Binder NK, de Alwis N, Beard S, Garg A, Kaitu'u-Lino TJ, and Hannan NJ
- Subjects
- Pregnancy, Female, Infant, Newborn, Humans, Animals, Mice, Ticagrelor pharmacology, Ticagrelor metabolism, Ticagrelor therapeutic use, Myometrium metabolism, Inflammation metabolism, Anti-Inflammatory Agents pharmacology, Premature Birth prevention & control, Premature Birth metabolism, Obstetric Labor, Premature prevention & control, Obstetric Labor, Premature metabolism
- Abstract
In Brief: Preterm birth is the leading cause of perinatal morbidity and mortality, and new therapies that delay preterm birth and improve neonatal outcomes are urgently needed. This study investigates whether ticagrelor inhibits uterine contractility and inflammation in preclinical in vitro, ex vivo (human) and in vivo (mouse) studies, to explore the potential of repurposing ticagrelor for the prevention of preterm birth., Abstract: Preterm birth remains a significant global health challenge, affecting approximately 10% of pregnancies and resulting in one million deaths globally every year. Tocolytic agents, used to manage preterm labour, have considerable limitations including lack of efficacy, and adverse side effects, emphasising the urgent need for innovative solutions. Here, we explore repurposing an antiplatelet cardioprotective drug, ticagrelor, as a potential treatment to prevent preterm birth. Ticagrelor has demonstrated pleiotropic actions beyond platelet inhibition, including relaxant effects on smooth muscle cells and anti-inflammatory effects in models of diabetes and sepsis. As preterm birth is underscored by inflammatory processes triggering uterine contractions, these actions position ticagrelor as an attractive candidate for prevention or delay of preterm birth. Utilising primary human myometrial tissue, human myometrial cells, and a mouse model of preterm birth, we investigated ticagrelor's potential as a safe and effective therapy for preterm birth. We showed that ticagrelor did not reduce the frequency or strength of spontaneous muscle contractions of ex vivo myometrial tissue nor did it reduce in vitro inflammation-induced contractility in myometrial cells. Additionally, ticagrelor did not exhibit the anticipated anti-inflammatory effects in myometrial cell culture experiments. In our mouse model of preterm birth, ticagrelor neither improved the preterm birth rate or fetal survival outcomes. Gene expression of pro-inflammatory cytokines and contraction-associated proteins in postpartum mouse uteri were unaltered by ticagrelor. In conclusion, ticagrelor is not a strong candidate to continue investigations in clinical trial for the treatment of preterm labour and prevention of preterm birth.
- Published
- 2024
- Full Text
- View/download PDF
241. The Regulation of Endothelin-1 in Pregnancies Complicated by Gestational Diabetes: Uncovering the Vascular Effects of Insulin.
- Author
-
Fato BR, Beard S, Binder NK, Pritchard N, Kaitu'u-Lino TJ, de Alwis N, and Hannan NJ
- Abstract
Gestational diabetes mellitus (GDM) is a condition of pregnancy defined by new-onset hyperglycemia. GDM is associated with impaired maternal endothelial and vascular reactivity. Endothelin-1 (ET-1) is a potent vasoconstrictor that contributes to endothelial dysfunction, however, its abundance and actions in GDM are unclear. Maternal plasma was obtained from pregnancies complicated by GDM ( n = 24) and gestation-matched controls ( n = 42); circulating ET-1 levels were assessed by ELISA. Human omental arteries from healthy pregnancies and those complicated by GDM were dissected from omental fat biopsies and collected at cesarean section. mRNA expression of ET-1 and its receptors, ET
A and ETB , in addition to vascular cell adhesion molecule-1 (VCAM1) and intercellular adhesion molecule-1 (ICAM1) were assessed by qPCR ( n = 28). Using wire myography, we investigated vascular constriction to ET-1 (10-11 -10-4 M) in omental arteries from pregnancies complicated by GDM, compared to gestation-matched controls ( n = 7). GDM cases were stratified by clinical management, diet intervention ( n = 5), or insulin treatment ( n = 6). Additionally, arteries from healthy pregnancies were treated with insulin (1 mU/mL ( n = 7) and 10 mU/mL ( n = 5)) or vehicle control. Vasoactive response to ET-1 was measured via wire myography. Circulating ET-1 levels and mRNA expression of the ET-1 system in omental arteries were not found to be significantly different between pregnancies complicated by GDM compared to healthy controls. However, we found insulin treatment during pregnancy and in ex vivo models reduced ET-1 vasoconstriction of maternal vasculature in GDM. These data suggest insulin may improve vascular function in GDM, however, further investigation is needed to define the role of ET-1 in pregnancy.- Published
- 2023
- Full Text
- View/download PDF
242. Cell surface associated protein mucin 15 (MUC15) is elevated in preeclampsia.
- Author
-
Nguyen A, Cannon P, Kandel M, Nguyen TV, Baird L, Wong G, Hannan NJ, Tong S, Bartho L, and Kaitu'u-Lino TJ
- Subjects
- Pregnancy, Humans, Female, Mucins metabolism, Brefeldin A metabolism, Trophoblasts metabolism, RNA, Messenger metabolism, Matrix Metalloproteinases metabolism, Placenta metabolism, Pre-Eclampsia metabolism
- Abstract
Background: Mucins are a family of proteins that protect the epithelium. A particular type of mucin, MUC15 is highly expressed in the placenta. This study aimed to characterise MUC15 in preeclampsia and investigate its role in placental stem cell biology., Methods: MUC15 mRNA and protein were measured in placentas from patients with early onset (<34 weeks' gestation) preeclampsia. Circulating serum MUC15 was measured via ELISA. MUC15 was localised in the placenta using in situ hybridisation. MUC15 mRNA expression was measured across differentiation of human trophoblast stem cells (hTSCs) to syncytiotrophoblast and extravillous trophoblasts. MUC15 was measured after syncytialised hTSCs were cultured in hypoxic (1% O
2 ) and proinflammatory (TNF α, IL-6) conditions. MUC15 secretion was assessed when syncytialised hTSCs were treated with brefeldin A (impairs protein trafficking) and batimastat (inhibits matrix metalloproteinases)., Results: MUC15 protein was significantly increased in the placenta (P = 0.0003, n = 32 vs n = 20 controls) and serum (P = 0.016, n = 32 vs n = 22 controls) of patients with preeclampsia, whilst MUC15 mRNA remained unchanged (n = 61 vs n = 18 controls). MUC15 mRNA (P = 0.005) and protein secretion (P = 0.006) increased following differentiation to syncytiotrophoblast cells. In situ hybridisation confirmed MUC15 localised to the syncytiotrophoblast cell within the placenta. Neither hypoxic or inflammatory conditions changed MUC15 mRNA expression or secretion. Brefeldin A treated hTSCs did not alter MUC15 secretion, whilst batimastat reduced MUC15 secretion (P = 0.044)., Conclusions: MUC15 is increased in early onset preeclampsia and is cleaved by matrix metalloproteinases. Increased MUC15 may reflect a protective mechanism associated with placental dysfunction. Further research will aid in confirming this., Competing Interests: Declaration of competing interest The authors have no conflicts of interest to declare for this manuscript., (Copyright © 2023 Elsevier Ltd. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
243. Using the methylome to predict pre-eclampsia.
- Author
-
Kaitu'u-Lino TJ, Bartho LA, and Tong S
- Subjects
- Female, Pregnancy, Humans, Epigenome, Pre-Eclampsia diagnosis, Pre-Eclampsia genetics
- Published
- 2023
- Full Text
- View/download PDF
244. Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant.
- Author
-
Bartho LA, Keenan E, Walker SP, MacDonald TM, Nijagal B, Tong S, and Kaitu'u-Lino TJ
- Abstract
Background: Lipids serve as multifunctional metabolites that have important implications for the pregnant mother and developing fetus. Abnormalities in lipids have emerged as potential risk factors for pregnancy diseases, such as preeclampsia and fetal growth restriction. The aim of this study was to assess the potential of lipid metabolites for detection of late-onset preeclampsia and fetal growth restriction., Methods: We used a case-cohort of 144 maternal plasma samples at 36 weeks' gestation from patients before the diagnosis of late-onset preeclampsia (n = 22), delivery of a fetal growth restricted infant (n = 55, defined as <5th birthweight centile), gestation-matched controls (n = 72). We performed liquid chromatography-tandem mass spectrometry (LC-QQQ) -based targeted lipidomics to identify 421 lipids, and fitted logistic regression models for each lipid, correcting for maternal age, BMI, smoking, and gestational diabetes., Findings: Phosphatidylinositol 32:1 (AUC = 0.81) and cholesterol ester 17:1 (AUC = 0.71) best predicted the risk of developing preeclampsia or delivering a fetal growth restricted infant, respectively. Five times repeated five-fold cross validation demonstrated the lipids alone did not out-perform existing protein biomarkers, soluble tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) for the prediction of preeclampsia or fetal growth restriction. However, lipids combined with sFlt-1 and PlGF measurements improved disease prediction., Interpretation: This study successfully identified 421 lipids in maternal plasma collected at 36 weeks' gestation from participants who later developed preeclampsia or delivered a fetal growth restricted infant. Our results suggest the predictive capacity of lipid measurements for gestational disorders holds the potential to improve non-invasive assessment of maternal and fetal health., Funding: This study was funded by a grant from National Health and Medical Research Council., Competing Interests: Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
245. Circulating Chemerin Is Elevated in Women With Preeclampsia.
- Author
-
Bartho LA, Kandel M, Walker SP, Cluver CA, Hastie R, Bergman L, Pritchard N, Cannon P, Nguyen TV, Wong GP, MacDonald TM, Keenan E, Hannan NJ, Tong S, and Kaitu'u-Lino TJ
- Subjects
- Female, Humans, Pregnancy, Biomarkers metabolism, Hypoxia metabolism, Placenta metabolism, Trophoblasts metabolism, Pre-Eclampsia diagnosis
- Abstract
Background: Preeclampsia is a severe complication of pregnancy. Chemerin is an adipokine secreted from adipose tissue and highly expressed in placenta. This study evaluated the biomarker potential of circulating chemerin to predict preeclampsia., Methods: Maternal plasma and placenta were collected from women with early-onset preeclampsia (<34 weeks), with preeclampsia and eclampsia, or before preeclampsia diagnosis (36 weeks). Human trophoblast stem cells were differentiated into syncytiotrophoblast or extravillous trophoblasts across 96 hours. Cells were cultured in 1% O2 (hypoxia) or 5% O2 (normoxia). Chemerin was measured by enzyme-linked immunosorbent assay (ELISA) and RARRES2 (gene coding chemerin) by reverse transcription-quantitative polymerase chain reaction., Results: Circulating chemerin was increased in 46 women with early-onset preeclampsia (<34 weeks) compared to 17 controls (P < .0006). Chemerin was increased in placenta from 43 women with early-onset preeclampsia compared to 24 controls (P < .0001). RARRES2 was reduced in placenta from 43 women with early-onset preeclampsia vs 24 controls (P < .0001). Chemerin was increased in plasma from 26 women with established preeclampsia (P = .006), vs 15 controls. Circulating chemerin was increased in 23 women who later developed preeclampsia vs 182 who did not (P = 3.23 × 10-6). RARRES2 was reduced in syncytiotrophoblast (P = .005) or extravillous trophoblasts (P < .0001). Hypoxia increased RARRES2 expression in syncytiotrophoblast (P = .01) but not cytotrophoblast cells., Conclusions: Circulating chemerin was elevated in women with early-onset preeclampsia, established preeclampsia, and preceding preeclampsia diagnosis of preeclampsia. RARRES2 was dysregulated in placenta complicated by preeclampsia and may be regulated through hypoxia. Chemerin may have potential as a biomarker for preeclampsia but would need to be combined with other biomarkers., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.)
- Published
- 2023
- Full Text
- View/download PDF
246. Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model.
- Author
-
Binder NK, de Alwis N, Beard S, Kadife E, Harper A, Kaitu'u-Lino TJ, Brownfoot FC, and Hannan NJ
- Subjects
- Pregnancy, Female, Male, Mice, Animals, Humans, Sulfasalazine pharmacology, Sulfasalazine therapeutic use, Blood Pressure, Disease Models, Animal, Nitric Oxide Synthase pharmacology, Vascular Endothelial Growth Factor Receptor-1, Nitric Oxide pharmacology, Pre-Eclampsia drug therapy, Hypertension
- Abstract
Introduction: Development of a therapeutic that targets the pathophysiological elements of preeclampsia would be a major advance for obstetrics, with potential to save the lives of countless mothers and babies. We recently identified anti-inflammatory drug sulfasalazine as a prospective candidate therapeutic for treatment of preeclampsia. In primary human cells and tissues in vitro, sulfasalazine potently decreased secretion of anti-angiogenic sFlt-1 and sENG, increased production of pro-angiogenic PlGF, mitigated endothelial dysfunction, and promoted whole vessel vasodilation., Methods: Using nitric oxide synthase antagonist Nω-Nitro-l-arginine methyl ester hydrochloride, a preeclampsia-like phenotype was induced in pregnant mice, including high blood pressure, fetal growth restriction, and elevated circulating sFlt-1. Mice were treated with sulfasalazine or vehicle from gestational day (D)13.5, with blood pressure measurements across gestation, fetal measurements at D17.5, and wire myograph assessment of vasoactivity., Results: Sulfasalazine had a modest effect on blood pressure, decreasing diastolic and mean blood pressure on D13.5, but not later in gestation, or systolic blood pressure. Sulfasalazine was not able to rescue fetal growth, in male or female fetuses. There was a suggestion of improved vasoactivity with sulfasalazine, but further clarification is required., Discussion: In this mouse model of preeclampsia, sulfasalazine did not sustain reductions in blood pressure nor affect fetal parameters of size and weight, both desirable attributes of a viable preeclampsia therapeutic. While these data suggest sulfasalazine might improve vasoactivity, murine toxicity considerations limited the dose range of sulfasalazine that could be tested in the current study., Competing Interests: Declaration of competing interest None., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
247. Repurposing existing drugs as a therapeutic approach for the prevention of preterm birth.
- Author
-
Arman BM, Binder NK, de Alwis N, Kaitu'u-Lino TJ, and Hannan NJ
- Subjects
- Infant, Newborn, Female, Pregnancy, Humans, Pharmaceutical Preparations, Drug Repositioning, Premature Birth prevention & control, Tocolytic Agents therapeutic use, Obstetric Labor, Premature drug therapy, Obstetric Labor, Premature prevention & control
- Abstract
In Brief: Preterm birth is the leading cause of perinatal morbidity and mortality; however, current therapies offer limited efficacy to delay birth and improve neonatal outcomes. This review explores the potential of repurposing drugs with known safety profiles to quench uterine contractions and inflammation, identifying promising agents for clinical trials., Abstract: Preterm birth is the leading cause of neonatal morbidity and mortality globally. Despite extensive research into the underlying pathophysiology, rates of preterm birth have not significantly reduced. Currently, preterm labour management is based on optimising neonatal outcomes. Treatment involves administering drugs (tocolytics) to suppress uterine contractions to allow sufficient time for transfer to an appropriate facility and administration of antenatal corticosteroids for fetal lung maturation. Current tocolytics are limited as they are associated with adverse maternal and fetal effects and only delay delivery for a short period. There has been a serious lack of therapeutic development for preterm birth, and new approaches to protect against or delay preterm birth are urgently needed. Repurposing drugs for the prevention of preterm birth presents as a promising approach by reducing the time and costs associated with pharmaceutical drug development. In this review, we explore the evidence for the potential of therapies, specifically proton pump inhibitors, tumour necrosis factor inhibitors, prostaglandin receptor antagonists, aspirin, and statins, to be repurposed as preventatives and/or treatments for preterm birth. Importantly, many of these innovative approaches being explored have good safety profiles in pregnancy. We also review how delivery of these drugs can be enhanced, either through targeted delivery systems or via combination therapy approaches. We aim to present innovative strategies capable of targeting multiple aspects of the complex pathophysiology that underlie preterm birth. There is an urgent unmet need for preterm birth therapeutic development, and these strategies hold great promise for improving neonatal outcomes.
- Published
- 2022
- Full Text
- View/download PDF
248. Placental DAAM2 is unaltered in preeclampsia, but upregulated by treatment with proton pump inhibitors.
- Author
-
de Alwis N, Beard S, Binder NK, Pritchard N, Tong S, Kaitu'u-Lino TJ, and Hannan NJ
- Subjects
- Female, Humans, Infant, Newborn, Pregnancy, Antioxidants metabolism, Esomeprazole therapeutic use, Hypoxia metabolism, Lansoprazole therapeutic use, Placenta metabolism, Prostaglandins F metabolism, Vascular Endothelial Growth Factor Receptor-1 metabolism, Pre-Eclampsia genetics, Pregnancy Proteins, Proton Pump Inhibitors therapeutic use, rho GTP-Binding Proteins metabolism, Microfilament Proteins metabolism
- Abstract
Background: Dishevelled Associated Activator Of Morphogenesis 2 (DAAM2) levels are elevated in the maternal circulation and placenta in pregnancies complicated by fetal growth restriction. However, placental DAAM2 levels in cases of preeclampsia have not previously been explored. Here, we examined placental DAAM2 in pregnancies complicated by preterm preeclampsia, and whether candidate preeclampsia therapeutics altered its expression., Methods: DAAM2 mRNA and protein levels were assessed in placental tissue from cases of preterm preeclampsia and gestation-matched controls (delivering ≤ 34 weeks; qPCR and western blot respectively). Short interfering RNAs were used to silence DAAM2 in isolated primary cytotrophoblast under normoxic (8 % O
2 ) and hypoxic (1 % O2 ) conditions, and expression of anti-angiogenic sFLT-1, angiogenic PGF, antioxidant, fetal growth, and inflammatory genes assessed. DAAM2 expression was measured in placental explant tissue from pregnancies complicated by preeclampsia, treated with three proton pump inhibitors (100 µM esomeprazole, lansoprazole, and rabeprazole)., Results: DAAM2 expression was significantly reduced in preeclamptic placental tissue compared to controls, but protein production was unchanged. Silencing DAAM2 in hypoxic cytotrophoblast increased sFLT-i13 isoform expression, but did not alter sFLT-e15a or PGF expression, or sFLT-1 secretion. DAAM2 knockdown did not alter expression of antioxidant (NQO-1, TXN, GCLC), fetal growth (SPINT1), or inflammasome (NLRP3) genes. Esomeprazole and lansoprazole, but not rabeprazole, increased DAAM2 expression in placental explant tissue from cases of preeclampsia., Conclusion: Placental DAAM2 protein is not significantly altered in placental tissue in cases of preeclampsia, and its suppression does not alter sFLT-1 secretion. Hence, placental DAAM2 is unlikely to drive the pathogenesis associated with preeclampsia., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
249. The effect of metformin on cardiovascular markers in female mice consuming a high fat diet.
- Author
-
de Alwis N, Binder NK, Mangwiro YTM, Pritchard N, Beard S, Kaitu'u-Lino TJ, Brownfoot F, and Hannan NJ
- Subjects
- Animals, Female, Mice, Biomarkers, Diet, High-Fat, Mice, Inbred C57BL, Cardiovascular Diseases etiology, Cardiovascular Diseases prevention & control, Metformin pharmacology, Metformin therapeutic use
- Abstract
Background: Metformin, widely used to treat diabetes, is now considered a candidate therapeutic for treatment of cardiovascular disease. This study aimed to assess whether metformin's non-glycaemic effects could mitigate cardiovascular disease indices in female mice consuming a high fat diet (HFD)., Methods: Four-week old female Arc:Arc(S) mice were placed on a standard (std) chow diet or Western-style HFD (22% fat, 0.15% cholesterol). At ∼8 months, the mice were administered 150 mg/kg metformin or vehicle (control) via intraperitoneal injection for 11 days. Blood pressure was measured (tail cuff plethysmography) at Day 9 and 11 of treatment. On Day 11, mice were weighed and culled. The mesenteric arcade and kidneys were collected for assessment of vascular reactivity (wire myography), and assessment of expression of cardiometabolic markers (qPCR), respectively., Results: The HFD fed female mice were significantly heavier than those receiving the std diet at 1-12 weeks on diet, and at cull. Mice on a std diet with metformin treatment were significantly heavier at cull than the mice on a std diet administered the control treatment. Metformin treatment did not alter the weight of the mice receiving the HFD. Neither the HFD (compared to the std diet), nor metformin treatment (compared to control treatment) altered blood pressure, vascular reactivity, or expression of cardiometabolic markers in the kidney., Conclusion: Consumption of a Western-style HFD (without high salt/sugar levels) did not alter the cardiovascular markers measured. Further studies are required to establish the non-glycaemic, cardio-protective effects of metformin in high-risk cohorts., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
250. Placental galectin-3 is reduced in early-onset preeclampsia.
- Author
-
Kandel M, Tong S, Walker SP, Cannon P, Nguyen TV, MacDonald TM, Hannan NJ, Kaitu'u-Lino TJ, and Bartho LA
- Abstract
Preeclampsia is a disease of pregnancy responsible for significant maternal and neonatal mortality. Galectin-3 is a β -Galactoside binding protein. This study aimed to characterise galectin-3 in women with preeclampsia and human trophoblast stem cells (hTSCs). Galectin-3 was measured in placental lysates and plasma collected from patients with early-onset preeclampsia (delivered <34 weeks' gestation) and gestation matched controls. Placental galectin-3 protein was significantly reduced in 43 women with early-onset preeclampsia compared to 21 controls. mRNA expression of LGALS3 (galectin-3 encoding gene) was reduced in 29 women with early-onset preeclampsia, compared to 18 controls ( p = 0.009). There was no significant difference in plasma galectin-3 protein in 46 women with early-onset preeclampsia compared to 20 controls. In a separate cohort of samples collected at 36 weeks' gestation, circulating galectin-3 was not altered in 23 women who later developed preeclampsia, versus 182 who did not. In syncytialised hTSCs, hypoxia increased mRNA expression of LGALS3 ( p = 0.01). Treatment with inflammatory cytokines (TNF-α and IL-6) had no effect on LGALS3 mRNA expression . However, TNF-α treatment caused an increase in mRNA expression of LGALS3BP (galectin-3 binding protein encoding gene) in hTSCs ( p = 0.03). This study showed a reduction of galectin-3 in placenta from pregnancies complicated by early-onset preeclampsia. LGALS3 mRNA expression was dysregulated by hypoxia exposure in placental stem cells., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Kandel, Tong, Walker, Cannon, Nguyen, MacDonald, Hannan, Kaitu’u-Lino and Bartho.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.